With Positive Boceprevir Data In Hand, Merck Prepares NDA Submission
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials evaluating the protease inhibitor in HCV met their primary endpoints but the real test is how boceprevir stacks up to Vertex's telaprevir.
You may also be interested in...
Vertex And Merck Neck-To-Neck In HCV Race
Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.
Vertex And Merck Neck-To-Neck In HCV Race
Vertex gets priority review for its protease inhibitor weeks after Merck announces its own accelerated timeline.
Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
The pharma announced Jan. 6 that boceprevir has been accepted for priority review by FDA, making an early-May action date likely.